Cross Country Healthcare Azioni (NASDAQ: CCRN)

Cross Country Healthcare (NASDAQ:CCRN) Azioni

CROSS COUNTRY HEALTHCARE INC

Cross Country Healthcare

Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare Inc

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 68.42 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $293.41 million which missed the analyst consensus estimate of $305.48 million by 3.95 percent. This is a 22.62 percent decrease over sales of $379.17 million the same period last year.

Earnings

Earnings Misses

News

CCRN

Cross Country Healthcare Q1 Adj. EPS $0.06, Inline, Sales $293.41M Miss $305.48M Estimate

U.S. stock futures rose on Friday following Thursday&#8217;s selloff that pushed the Nasdaq 100 index into the correction zone. Futures of all four benchmark indices rose in premarket trading.
President Donald Trump&#8216;s administration postponed implementation of certain USMCA goods that are imported from Mexico and Canada on Thursday after a 25% levy was implemented on Tuesday.
Investors await the U.S. jobs report, unemployment rate and hourly wages data for February, slated to be released today.
Meanwhile, the 10-year Treasury yield stood at 4.26%, while the two-year yield was at 3.95%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 91% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.48%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.15%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.19%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Friday. SPY gained 0.33% to $574.58, and QQQ was up 0.48% to $490.55, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, information technology, and consumer discretionary sectors experienced the most significant losses on Thursday, contributing to the overall market decline. Conversely, energy stocks bucked the trend, closing higher amidst the widespread downturn.
On the economic front, the U.S. reported a record trade deficit of $131.4 billion in January, compared to a revised $98.1 billion gap in the previous month. Unit labor costs in the nonfarm business sector rose 2.2% in the fourth quarter, compared to preliminary expectations of 3%.
Initial jobless claims declined by 21,000 from the previous week to 221,000 during the last week of February, compared to market estimates of 235,000.
Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) reported better-than-expected earnings for its fourth quarter.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.61%</td>
<td>18,069.26</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.78%</td>
<td>5,738.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.99%</td>
<td>42,579.08 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.63%</td>
<td>2,066.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
While markets have reacted negatively to recent tariff announcements, this suspension could set the stage for a potential market recovery in the medium term, explained Subho Moulik, the founder and CEO of the fintech platform Appreciate.
&#8220;Despite legitimate concerns about inflation and trade uncertainty, U.S. economic fundamentals remain solid with unemployment edging down to 4% and GDP growth still in the positive territory. This economic resilience provides a foundation for market stabilization,&#8221; Moulik added.
According to him, market volatility may persist in the short term, but history demonstrates that strategic navigation of policy-induced corrections can lead to outperformance for investors who maintain discipline and a long-term perspective.
The Nasdaq 100 entered correction territory on Thursday, falling 9.76% from its record high to 20,052.64, and breaking below its 200-day moving average for the first time in nearly two years.
Analyst Jason Goepfert of White Oak Consultancy LLC warned in an X post that a further 3.5% decline within the next two weeks would signal a bear market.
Historically, when the index has broken its 200-day average after a prolonged uptrend and subsequently dropped at least 3.5% within two weeks, a bear market has followed. Conversely, if the index avoids a 3.5% drawdown in the next two weeks, historical data suggests positive one-year returns.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Nasdaq 100 <a href="https://twitter.com/search?q=%24QQQ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$QQQ</a> closed below its 200-day average for the first time in over a year. Watch the next 2 weeks. Every time it lost its 200-day after an extended run and suffered at least a -3.5% drawdown within the next 2 weeks, it led to a bear market. When the 2-week… <a href="https://t.co/m4zOyP86da">pic.twitter.com/m4zOyP86da</a>
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1897754090748186951?ref_src=twsrc%5Etfw">March 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Charlie Bilello, the chief market strategist at Creative Planning, the 497 trading sessions for which the Nasdaq 100 index was above its 200-day moving average, was the second longest streak in its history, returning 73% to investors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Nasdaq 100 Index gained 73% during this historic uptrend&#8230; <a href="https://t.co/B8gvLWF30V">pic.twitter.com/B8gvLWF30V</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1897767711901368334?ref_src=twsrc%5Etfw">March 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ryan Detrick of Carson Research highlighted historical data and said that the market has peaks in mid-February and hits lows in the second week of March over the last 20 years.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Over the past 20 years, peaks in mid-February and lows in the second week of March are common. Could it really happen again? <a href="https://t.co/42eJLQeIIW">pic.twitter.com/42eJLQeIIW</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1897782202370572689?ref_src=twsrc%5Etfw">March 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Friday:
<ul>
<li>February&#8217;s U.S. jobs report, unemployment rate and hourly wages data will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Michelle Bowman will speak at 10:15 a.m., New York Fed President John Williams will speak again at 10:45 a.m., Fed Governor Adriana Kugler will speak at 12:20 p.m., and Fed Chairman Jerome Powell will speak at 12:30 p.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s consumer credit data will be announced at 3:00 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Algonquin Power &amp; Utilities Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) was up 1.21% in the premarket on Friday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 8 cents per share on revenue of $607.00 million.</li>
</ul>
<ul>
<li>Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) slipped 0.15% as Wall Street expects it to report quarterly earnings of $3.31 per share on revenue of $784.85 million before the opening bell.</li>
</ul>
<ul>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) gained 5.51% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 12 cents per share on revenue of $863.41 million.</li>
</ul>
<ul>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) jumped 12.84% after reporting better-than-expected first-quarter financial results. The company said it expects second-quarter revenue of approximately $14.9 billion, versus estimates of $14.76 billion.</li>
</ul>
<ul>
<li>JD.Com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) fell 1.98% despite better-than-expected earnings as management did not clarify on the scale and profitability of its new food delivery business JD Takeaway.</li>
</ul>
<ul>
<li>Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) dropped 1.42% after it reported mixed second quarter earnings but the management said that they were &#8220;well equipped&#8221; to mitigate tariffs.</li>
</ul>
<ul>
<li>Plus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) surged 58.33% as it received Orphan Drug Designation from the FDA for its drug Rhenium Obisbemeda which is used to treat leptomeningeal metastases in lung cancer patients.</li>
</ul>
<ul>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) climbed 5.97% after it released a whitepaper, &#8220;Deepfake Countermeasures,&#8221; detailing their deepfake detection system, which boasts billion-to-one accuracy and 35-millisecond matching.</li>
</ul>
<ul>
<li>Cross Country Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) plunged 42.97% as it missed fourth quarter estimates and Federal Trade Commission&#8217;s review of its $615 million sale to Aya Healthcare discovered some &#8220;troubling documents&#8221;.</li>
</ul>
<ul>
<li>Hewlett Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) plummeted 20.49% on earnings miss and weak revenue outlook amid job cut announcement.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.25% to hover around $67.19 per barrel.
The gold spot index was up by 0.24% to $2,918.13 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was down 0.44% at the 103.609 level.
Asian markets closed lower on Friday as the Australia's ASX 200, India's S&amp;P BSE Sensex, China's CSI 300, South Korea's Kospi, Japan's Nikkei 225, and Hong Kong's Hang Seng index declined. European markets were also lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44185877/costco-ceo-says-it-is-well-equipped-to-mitigate-trumps-tariffs-but-warns-of-inflation-impact-on-consumers-when-it-rains-it-rains-on-everyone">Costco CEO Says It Is &#8216;Well Equipped&#8217; To Mitigate Trump&#8217;s Tariffs, But Warns Of Inflation Impact On Consumers: &#8216;When It Rains, It Rains On Everyone&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Market Summary

Futures

Pre-Market Outlook

Markets

AUID

AVGO

COST

PSTV

US Stocks Likely To Open Higher After Nasdaq 100 Enters Correction Zone: 'Economic Resilience Provides A Foundation For Market Stabilization,' Says Expert

Rumors

Movers

Trading Ideas

Watching Shares Of Cross Country Healthcare; Traders Circulate Comments From M&A Blog

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.12 by 66.67 percent. This is a 86.21 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $309.940 which missed the analyst consensus estimate of $306.100 million by 100.00 percent. This is a 100.00 percent decrease over sales of $414.035 million the same period last year.

Cross Country Healthcare Q4 2024 Adj. EPS $0.04 Misses $0.12 Estimate, Sales $309.940 Miss $306.100M Estimate

Cross Country Healthcare, Inc. ("Cross Country" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) today announced that the Company has obtained all requisite stockholder approvals in connection with its proposed acquisition by Aya Healthcare.
As previously disclosed, Cross Country and Aya Healthcare expect to complete the transaction in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the NASDAQ.

Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

JMP Securities analyst Constantine Davides reiterates Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Perform on Cross Country Healthcareto Market Perform

Barrington Research analyst Kevin Steinke downgrades Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) from Outperform to Market Perform.

Downgrades

Barrington Research Downgrades Cross Country Healthcare to Market Perform

Truist Securities analyst Tobey Sommer maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Hold and raises the price target from $15 to $18.61.

Price Target

Truist Securities Maintains Hold on Cross Country Healthcare, Raises Price Target to $18.61

<h3>Gainers</h3>
<ul>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares rose 225.5% to $5.24 during Wednesday's pre-market session. The company's market cap stands at $14.2 million. </li>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock rose 66.94% to $1.97. The market value of their outstanding shares is at $299.6 million. </li>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) stock moved upwards by 62.36% to $18.12. The market value of their outstanding shares is at $612.6 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 32.97% to $0.48. The market value of their outstanding shares is at $24.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 26.42% to $17.7. The company's market cap stands at $38.4 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares increased by 21.0% to $0.2. The company's market cap stands at $7.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock decreased by 74.7% to $0.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $21.1 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 12.55% to $20.99. The company's market cap stands at $30.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares fell 11.73% to $0.48. The company's market cap stands at $4.2 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 9.26% to $0.36. The market value of their outstanding shares is at $6.0 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares fell 9.04% to $0.74. The company's market cap stands at $3.7 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 8.7% to $0.6. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMRA

CYCN

CYTH

ERNA

FBRX

HRTX

QNRX

RLMD

VIRX

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday.
The Dow traded up 0.30% to 44,838.93 while the NASDAQ rose 0.80% to 19,637.25. The S&amp;P 500 also rose, gaining, 0.23% to 6,063.99.
Check This Out: <a href="https://www.benzinga.com/24/12/42287319/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Wednesday.
In trading on Wednesday, energy shares fell by 1.9%.
Top Headline
The ISM services PMI fell to 52.1 in November compared to 56 in October and down from market estimates of 55.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cross Country Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) shares shot up 62% to $18.14 after Aya Healthcare announced a definitive agreement to acquire the company for approximately $615 million.</li>
<li>Shares of CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) got a boost, surging 102% to $0.6384 after the company announced it has been granted a 180-day extension by Nasdaq to regain compliance with its $1.00 minimum bid price requirement.</li>
<li>SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares were also up, gaining 89% to $1.19 after the company announced its online sales on Amazon grew 417% since September.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Relmada Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares dropped 77% to $0.6438 after the company announced its Reliance II Phase 3 study indicated results were futile and unlikely to meet the primary efficacy endpoint with statistical significance.</li>
<li>Shares of Torrid Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) were down 31% to $3.18 after the company reported worse-then-expected third-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>PSQ Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) was down, falling 36% to $4.9005 after the company announced a $36.2 million registered direct offering of common stock.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.88 while gold traded up 0.2% at $2,673.60.
Silver traded up 0.9% to $31.780 on Wednesday, while copper rose 0.1% to $4.2045.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.32%, Germany's DAX climbed 0.96% and France's CAC 40 rose 0.53%. Spain's IBEX 35 Index rose 0.76%, while London's FTSE 100 fell 0.27%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 0.07%, Hong Kong's Hang Seng Index falling 0.02%, China's Shanghai Composite Index falling 0.42% and India's BSE Sensex gaining 0.14%.
Economics
<ul>
<li>U.S. private businesses added 146K workers to their payrolls for the month of November compared to a revised 184K gain in October, and versus market estimates of 150K.</li>
<li>The S&amp;P Global services PMI was revised downward to 56.1 in November versus a preliminary reading of 57, and compared to October's reading of 55.</li>
<li>U.S. factory orders rose by 0.2% from the previous month to $586.7 billion in October.</li>
<li>The ISM services PMI fell to 52.1 in November compared to 56 in October and down from market estimates of 55.5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42313903/top-3-tech-and-telecom-stocks-that-may-implode-this-quarter">Top 3 Tech And Telecom Stocks That May Implode This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CNEY

CURV

PSQH

Nasdaq Surges 150 Points; ISM Services PMI Falls In November

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Shares of Pure Storage Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) gained 26.1% to $67.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter <a href="https://www.benzinga.com/news/earnings/24/12/42303442/pure-storage-shares-soar-after-strong-q3-q4-guidance-above-estimates-details">guidance above estimates</a>.
Pure Storage reported quarterly earnings of 50 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $831.07 million which beat the consensus estimate of $818.14 million and is an increase over sales of $762.84 million from the same period last year.
Pure Storage shares jumped 26.1% to $67.48 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Cross Country Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) shares gained 61.9% to $18.07 after Aya Healthcare announced a definitive agreement to acquire the company for approximately $615 million.</li>
<li>Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) surged 22.4% to $10.76.</li>
<li>Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) climbed 22% to $117.05 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates on Tuesday.</li>
<li>Hesai Group – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) gained 20.6% to $9.65.</li>
<li>Stoke Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) jumped 15.2% to $13.17 after the company announced it received breakthrough therapy designation status from the FDA for Zorevuvnersen.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 15.1% to $3.6150.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 14.6% to $16.97.</li>
<li>MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) gained 14.2% to $19.85.</li>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 14.2% to $1.61.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) rose 13.3% to $27.10 after the company announced a 106% year-over-year usage increase for its marketing platform from Thanksgiving to Cyber Monday.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) gained 12.4% to $9.99.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 10.2% to $83.41. Needham maintained a Buy rating on the stock.</li>
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) gained 9.2% to $362.05 following third-quarter results.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) surged 8.8% to $292.50.</li>
<li>UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) rose 8.5% to $15.61.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) gained 7.2% to $6.49.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) rose 6.6% to $345.27 after Baird maintained an Outperform rating on the stock and raised its price target from $305 to $380.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42314096/att-to-rally-around-14-here-are-10-top-analyst-forecasts-for-wednesday">AT&amp;T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

BTDR

HSAI

JBLU

MRVL

MVST

NVTS

PATH

POWL

PSTG

ROKU

SOUN

STOK

ZETA

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday

Cross Country Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) shares are rocketing premarket on Wednesday after the company inked a deal to be acquired by Aya Healthcare for $18.61 per share in an all-cash <a href="https://www.benzinga.com/pressreleases/24/12/b42312526/aya-healthcare-to-acquire-cross-country-healthcare-for-approximately-615-million-in-cash" target="_blank" rel="noreferrer noopener">transaction valued at around $615 million</a>.
This price represents a 67% premium over Cross Country&#8217;s closing price on December 3, 2024, and a 68% premium over its 30-day volume-weighted average trading price ending on the same date.
The merger will expand Aya&#8217;s services by adding Cross Country&#8217;s clinical offerings in non-clinical settings such as schools and homes, alongside Aya&#8217;s expertise in travel nursing, allied health, and staffing for per diem, permanent roles, interim leadership, locum tenens, and non-clinical professionals nationwide.
Together, the companies aim to reduce care costs, improve clinical outcomes, and provide better staffing solutions, while also offering employees growth opportunities through shared best practices.
The transaction is expected to close in the first half of 2025, pending approval from Cross Country&#8217;s stockholders and other customary conditions.
The Cross Country Board of Directors has unanimously approved the agreement and will recommend stockholders vote in favor at a Special Meeting of Stockholders, which will be scheduled shortly.
Once the transaction is complete, Cross Country will become a private company, and its common stock will be delisted from NASDAQ.
John A. Martins, President and Chief Executive Officer of Cross Country, said, &#8220;This compelling all-cash transaction will deliver significant and immediate value to our stockholders. Importantly, it will also enhance and expand services and solutions for our clients, provide a wider array of opportunities and efficiencies for our healthcare clinicians and create new opportunities for our employees as part of an industry leader with a complementary footprint and offering.&#8221;
Alan Braynin, president and Chief Executive Officer of Aya, said, &#8220;By combining our strengths, resources and unwavering commitment to delivering best-in-class talent solutions, we are uniquely positioned to offer enhanced value to our healthcare systems, schools, clinicians and non-clinical professionals.&#8221;
Price Action: CCRN shares are up 62.9% at $18.18 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42310095" target="_blank" rel="noreferrer noopener">AAPL Stock Hits New High Despite Sales Slowdown: Tech Bull Says &#8216;Street Is Realizing&#8217; iPhone 16 Marks The &#8216;Start Of A Super Cycle&#8217; For Apple</a></li>
</ul>
Photo via Shutterstock.

Small Cap

Cross Country Healthcare Agrees To Be Acquired By Aya Healthcare, Shareholders To Receive 67% Premium

WIIM

Cross Country Healthcare shares are trading higher after Aya Healthcare announced a definitive agreement to acquire the company for approximately $615 million.

Aya Healthcare Entered Into A Definitive Agreement To Acquire Cross Country For $18.61 Per Share In Cash In A Transaction Valued At Approximately $615M

Benchmark analyst Bill Sutherland maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Buy and lowers the price target from $19 to $18.

Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $18

Guidance

Cross Country Healthcare Sees Q4 Adj. EPS $0.10-$0.14, Revenue $300M-$310M

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

Earnings Beats

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Cross Country Healthcare will report an earnings per share (EPS) of $0.10.
The market awaits Cross Country Healthcare's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 3.78% drop in the share price on the subsequent day.
Here's a look at Cross Country Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.17</td>
<td>0.27</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.19</td>
<td>0.29</td>
<td>0.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-6.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730818974_0.png" alt="eps graph" />
<h3>Performance of Cross Country Healthcare Shares</h3>
Shares of Cross Country Healthcare were trading at $11.22 as of November 04. Over the last 52-week period, shares are down 39.44%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CCRN/earnings">To track all earnings releases for Cross Country Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Cross Country Healthcare's Future Earnings

Truist Securities analyst Tobey Sommer maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Hold and lowers the price target from $17 to $15.

Truist Securities Maintains Hold on Cross Country Healthcare, Lowers Price Target to $15

&nbsp;S&amp;P SmallCap 600 constituent SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) is spinning off Curbline Properties in a transaction expected to be completed on October 1.
Cross Country Healthcare is no longer representative of the small-cap market space.&nbsp;

CURBw

SITC

Curbline Properties To Be Added To S&P SmallCap 600 Effective Prior To Open Of Trading On October 1, Replacing Cross Country Healthcare

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, CCRN, OMC on Behalf of Shareholders

CROSS COUNTRY HEALTHCARE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cross Country Healthcare, Inc. - CCRN

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CCRN and LBRDA on Behalf of Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Encourages Stockholders of EMKR, CCRN, WMPN, ALVR to Act Now

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCRN, IPG, LBRDA, EMKR on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCRN, WMPN, EMKR, ALVR on Behalf of Shareholders

Cross Country Healthcare Announces Fourth Quarter and Full Year 2024 Financial Results

Nursing in 2025: No Relief in Sight as Burnout, Stress & Short Staffing Persist

Cross Country Healthcare Announces First Quarter 2025 Financial Results

ALVR

EMKR

LBRDA

OMIC

WMPN

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Cross Country Healthcare

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO